A Diagnostics Industry Roundtable: Where is Growth?
An unprecedented wave of consolidations has everyone in diagnostics pondering what's next. Four top industry executives discuss the future of consolidation, the need for broader product lines to attract large-volume buyers, and the need to eliminate excess capacity from the system. New product opportunities exist, but the high cost of R&D will likely force more collaborations, particularly with medical device and drug companies.
You may also be interested in...
For more than a year, Dade Behring has been wading through a financial morass that is likely to lead to bankruptcy, a sale of assets, or a reorganization of capital structure. As concerns mount about its long-term prospects, Dade Behring and its lenders are seeking to restructure the company's burdensome long-term debt. While stubborn lenders have been unwilling to accept less than a near-to-full return on their investment, several events this spring seem to be motivating them to be more flexible.
Thermo Fisher Scientific has agreed to buy Mesa Biotech for $450m in cash and Hillrom will acquire Bardy Diagnostics for $375m in cash. Both deals will add complementary digital health solutions, which may be a continued trend in 2021.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.